Drug Use Research & Management Program
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Thursday, April 26, 2012 1:00-4:00 PM
Clackamas Community Training Center
29353 SW Town Center Loop East
Wilsonville, OR 97070

MEETING MINUTES

Members Present: Zahia Esber, MD; Phillip Levine, PhD; Meena Mital, MD; William Origer, MD; David Pass, MD; James Slater, PharmD; Cathy Zehrung, RPh
Members Present by Phone: Joshua Bishop, PharmD; Stacy Ramirez, PharmD; Atif Zaman, MD (Ad-Hoc Member)
Staff Present: Roger Citron, RPh; Megan Herink, PharmD, BCPS; Kathy Ketchum, RPh, MPA:HA; Ann Hamer, PharmD, BCPP; Kathy Sentena, PharmD; Ted Williams, PharmD; Valerie Smith; Richard Holsapple, RPh; Ralph Magrish, MPA; Amy Burns, PharmD
Audience: Robert Jaramillo (Forest); Nate Miles; Kathy Kirk (OPMC); Alex Smith, Jim Graves (BMS); Anne Murray (BMS); Robert Chang (BMS); John Peterson (Gilead); Yoona Kim (Gilead); Deborah Wafer (Gilead); Mike Willet (Pfizer); Barry Benson (Merck); Lisa Valalka (Genzyme); Jeana Colabianchi (Sunovion); Michael Dutro (Pfizer); Julie Preston (Optimer) Daniko Webb (Actelion); Venus Holder (Lilly); Justin Druino (Lilly); Steve Wright (Boehringer Ingelheim); Mike Donabedan (Vertex); George Yauntzke (Actelion); Lorren Sandt (Caring Ambassadors); David Barba (Forest); Don Stetcher (Novartis); Paul Nielsen (MedImmune); Robert Kosesan; Molly Gelletz (Sunovion); Chris Bounoff (NAMI)

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to coverage, PDL composition, or utilization control recommendations to the OHA.

I. CALL TO ORDER
- a. The meeting was called to order at approximately 1pm.
- b. Conflict of interest declarations were reviewed and no new conflicts were reported. Dr. Zaman's conflict of interest was presented to the members.
- c. The March 26, 2012 meeting minutes were reviewed.

ACTION: Approved as is.

II. ProDUR
- a. Dr. Burns presented on Kalydeco® (ivacaftor) recommending prior authorization criteria restricting use to genotype G551D.

***ACTION:** Approved as is.
- b. Mr. Citron presented the 15-day initial supply concept. Chris Bounoff with National Association for the Mentally Ill (NAMI) presented public comment on the issue.

***ACTION:** Committee was supportive of the idea but asked staff to present information on class adherence rates and experiences from other states after implementation. There was also concern regarding additional copays and how that would be addressed.
- c. Dr. Herink presented a new drug evaluation on Egrifta® (tesamorelin) recommending prior authorization criteria be implemented to ensure use for covered diagnoses and restrict use for lipodystrophy.

***ACTION:** Approved as is. III. NEW BUSINESS

**Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)*

a. Dr. Sentena presented diabetes medications class update recommending updates to the Amylin Analogs, Incretin Enhancers and Incretin Mimetics prior authorization criteria, adding Tradjenta® (linagliptin) and Bydureon® (exenatide) and making linagliptin, linagliptin/metformin, saxagliptin, sitagliptin.simvastatin, sitagliptin/metformin ER non-preferred.

***ACTION**: Approved as is after Executive Session.

b. Dr. Herink presented a new drug evaluation for Dificid® (fidaxomicin) recommending that metronidazole 250mg and 500mg tablets and vancomicin 125mg & 250mg capsules and vancomycin IV vials be preferred and fidaxomicin be non-preferred and prior authorization criteria be implemented to ensure first line treatments were tried and failed.

***ACTION:** The Committee approved the recommendation but asked for an Infectious Disease consult to address lingering questions of disease severity identification, the resistance risk posed by preferring vancomycin and the appropriateness of metronidazole as a single first-line agent.

c. Dr. Hamer presented the Antidepressant new drug reviews recommending to make vilazodone non-preferred and include a dose limit for citalopram. Robert Jaramillo with Forest presented public comment on Viibryd.

***ACTION:** Approved after Executive Session. In addition selegiline patches were made non-preferred and generic escitalopram was recommended blocked with open access to the brand until the price decreases.

d. Dr. Burns presented the Smoking Cessation class update recommending that the Nicotine Replacement Therapy Class be added to the preferred drug list making Nicotrol and Nicotrol NS non-preferred and to include patches, gum, lozenges, buproprion sustained release as preferred with a 6 month quantity limit and varenicline as preferred with a 12 week quantity limits. Michael Dutro with Pfizer presented public comment.

***ACTION:** Approved after Executive Session with the recommendation of requiring prior authorization for second attempt of smoking cessation to require behavioral therapy.

e. Dr. Herink presented drug class scans.

1. Pulmonary Arterial Hypertension – Recommended that continue current prior authorization criteria to ensure appropriate patient selection. John Peterson from Gilead presented public comment on Letairis. George Yauhtzke from Actelion presented public comment on Tracleer.

***ACTION:** Approved after Executive Session.

2. Oral Hypoglycemics/TZDs – Recommended leaving the class as is.

**ACTION*: Approved after Executive Session.

3. Insulins – Recommended leaving the class as is.

**ACTION*: Approved after Executive Session.

IV. OLD BUSINESS

a. Dr. Herink presented on Hepatitis B recommending that prior authorization criteria be established for non-preferred products and making entacavir non-preferred. Ad-Hoc expert Dr. Atif Zaman agreed with the recommendations presented.

**ACTION*: Approved after Executive Session.

V. The meeting was adjourned at approximately 4pm.